Trevi Therapeutics, Inc. TRVI
We take great care to ensure that the data presented and summarized in this overview for Trevi Therapeutics, Inc. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding TRVI
View all-
Nea Management Company, LLC Timonium, MD11.4MShares$44.6 Million2.9% of portfolio
-
Frazier Life Sciences Management, L.P. Menlo Park, CA7.38MShares$28.9 Million1.33% of portfolio
-
Rubric Capital Management LP New York, NY5.03MShares$19.7 Million0.47% of portfolio
-
Viking Global Investors LP4.4MShares$17.2 Million0.06% of portfolio
-
Vr Adviser, LLC New York, NY3.42MShares$13.4 Million1.18% of portfolio
-
Vanguard Group Inc Valley Forge, PA3.26MShares$12.8 Million0.0% of portfolio
-
Black Rock Inc. New York, NY3.14MShares$12.3 Million0.0% of portfolio
-
Logos Global Management LP San Francisco, CA2.75MShares$10.8 Million1.22% of portfolio
-
Opaleye Management Inc. Boston, MA2.57MShares$10.1 Million1.57% of portfolio
-
Vivo Capital, LLC Palo Alto, CA1.61MShares$6.32 Million0.79% of portfolio
Latest Institutional Activity in TRVI
Top Purchases
Top Sells
About TRVI
Trevi Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of Haduvio to treat serious neurologically mediated conditions. The company is developing Haduvio, an oral extended-release formulation of nalbuphine, which is in phase IIb/III clinical trial for the treatment of chronic pruritus, chronic cough in patients with idiopathic pulmonary fibrosis. It has a license agreement with Endo Pharmaceuticals Inc. to develop and commercialize products incorporating nalbuphine hydrochloride in any formulation. The company was incorporated in 2011 and is headquartered in New Haven, Connecticut.
Insider Transactions at TRVI
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Jan 08
2025
|
Lisa Delfini Chief Financial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
5,000
+7.18%
|
$0
$0.51 P/Share
|
|
Jan 07
2025
|
Lisa Delfini Chief Financial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
1,000
+1.65%
|
$0
$0.51 P/Share
|
|
Dec 13
2024
|
Christopher Galletta |
BUY
Exercise of conversion of derivative security
|
Direct |
15,000
+42.94%
|
$0
$0.51 P/Share
|
|
Sep 09
2024
|
Jennifer L Good President & CEO |
SELL
Open market or private sale
|
Direct |
1,840
-0.86%
|
$5,520
$3.04 P/Share
|
|
Sep 09
2024
|
Jennifer L Good President & CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
1,840
+0.85%
|
$1,840
$1.43 P/Share
|
|
Sep 06
2024
|
Jennifer L Good President & CEO |
SELL
Open market or private sale
|
Direct |
4,219
-1.94%
|
$12,657
$3.03 P/Share
|
|
Sep 06
2024
|
Jennifer L Good President & CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
4,219
+1.9%
|
$4,219
$1.43 P/Share
|
|
Sep 05
2024
|
Jennifer L Good President & CEO |
SELL
Open market or private sale
|
Direct |
40,277
-15.88%
|
$120,831
$3.11 P/Share
|
|
Sep 05
2024
|
Jennifer L Good President & CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
40,277
+13.71%
|
$40,277
$1.43 P/Share
|
|
Sep 04
2024
|
Jennifer L Good President & CEO |
SELL
Open market or private sale
|
Direct |
10,981
-4.9%
|
$32,943
$3.02 P/Share
|
|
Sep 04
2024
|
Jennifer L Good President & CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
10,981
+4.67%
|
$10,981
$1.43 P/Share
|
|
Sep 03
2024
|
Jennifer L Good President & CEO |
SELL
Open market or private sale
|
Direct |
3,863
-1.78%
|
$11,589
$3.02 P/Share
|
|
Sep 03
2024
|
Jennifer L Good President & CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
3,863
+1.75%
|
$3,863
$1.43 P/Share
|
|
Aug 27
2024
|
David P Meeker |
SELL
Open market or private sale
|
Direct |
4,555
-1.28%
|
$9,110
$2.93 P/Share
|
|
Aug 27
2024
|
David P Meeker |
BUY
Exercise of conversion of derivative security
|
Direct |
4,555
+1.26%
|
$4,555
$1.43 P/Share
|
|
Aug 19
2024
|
Thomas Sciascia Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
16,496
-6.97%
|
$32,992
$2.96 P/Share
|
|
Aug 19
2024
|
Thomas Sciascia Chief Scientific Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
16,496
+6.51%
|
$16,496
$1.43 P/Share
|
|
Aug 16
2024
|
Thomas Sciascia Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
18,660
-7.81%
|
$37,320
$2.76 P/Share
|
|
Aug 16
2024
|
Thomas Sciascia Chief Scientific Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
18,660
+7.24%
|
$18,660
$1.43 P/Share
|
|
Aug 15
2024
|
Thomas Sciascia Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
12,745
-5.47%
|
$25,490
$2.79 P/Share
|
Last 12 Months Summary
| Exercise of conversion of derivative security | 240K shares |
|---|
| Open market or private sale | 201K shares |
|---|